Profound Medical Corp. 8-K Filing

FAQ

Key Financial Figures

• $7.00 — res"), at a per share purchase price of $7.00 (the "Offering") for aggregate gross pr
• $6.45 million — ering") for aggregate gross proceeds of $6.45 million. The Offering closed on December 30, 20

Filing Documents

• tm2534550d1_8k.htm (8-K) — 31KB
• tm2534550d1_ex10-1.htm (EX-10.1) — 277KB
• tm2534550d1_ex99-1.htm (EX-99.1) — 10KB
• 0001104659-25-125344.txt ( ) — 530KB
• prof-20251230.xsd (EX-101.SCH) — 3KB
• prof-20251230_lab.xml (EX-101.LAB) — 33KB
• prof-20251230_pre.xml (EX-101.PRE) — 22KB
• tm2534550d1_8k_htm.xml (XML) — 3KB

01 Entry into a Material Definitive

Item 1.01 Entry into a Material Definitive Agreement. On December 30, 2025, Profound Medical Corp. (the "Company") entered into a subscription agreement (the "Subscription Agreement") with certain Canadian investors (the "Investors") providing for the private placement of an aggregate of 921,428 shares of the Company's common shares (the "Shares"), at a per share purchase price of $7.00 (the "Offering") for aggregate gross proceeds of $6.45 million. The Offering closed on December 30, 2025. The Subscription Agreement contains customary representations, warranties, and covenants of the Company and the Investors and other obligations of the parties. The offering and sale of the Shares were made in reliance upon the exemption from registration provided by Regulation S under the Securities Act of 1933, as amended (the "Securities Act"), as the transactions were completed outside the United States with non-U.S. persons. The Shares are subject to transfer restrictions and may not be offered to be sold in the United States absent registration or an applicable exemption under the Securities Act. The Company intends to file a registration statement for the resale of the Shares within four months after the closing of the Offering. The foregoing description of the Subscription Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the form of Subscription Agreement filed with this Current Report on Form 8-K as Exhibit 10.1 and incorporated herein by reference.

02 Unregistered Sales of Equity

Item 3.02 Unregistered Sales of Equity Securities. The information contained under Item 1.01 of this Current Report on Form 8-K is incorporated by reference herein.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On December 30, 2025, Profound Medical Corp. (the "Company") issued a press release announcing the closing of the Offering. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, or the Securities Act. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the U.S. Securities Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Form of Subscription Agreement, dated December 30, 2025 99.1 Press Release, dated December 30, 2025 104 Cover Page Interactive Data File (embedded within Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROFOUND MEDICAL CORP. Date: December 30, 2025 By: /s/ Rashed Dewan Rashed Dewan Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR